HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas.

Abstract
Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunotherapy outcomes in breast cancer using several public databases. The possible treatment target TNF superfamily member 4 (TNFSF4) was selected from many candidates based on its abnormal expression profile, survival-associated status, and ability to predict immune system reactions. For the first time, we identified the oncogenic features of TNFSF4 in breast carcinoma. TNFSF4 was revealed to be closely related to treatment that induced antitumor immunity and to interact with multiple immune effector molecules and T cell signatures, which was independent of endocrine status and has not been reported previously. Moreover, the potential immunotherapeutic approach of TNFSF4 blockade showed underlying effects on stem cell expansion, which more strongly and specifically demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast carcinomas. We identified potential targets that may contribute to breast cancer therapies through clinical analysis and real-world review and provided one potential but crucial tool for treating breast carcinoma that showed effects across subtypes and long-term effectiveness.
AuthorsKai Li, Lei Ma, Ye Sun, Xiang Li, Hong Ren, Shou-Ching Tang, Xin Sun
JournalScientific reports (Sci Rep) Vol. 11 Issue 1 Pg. 18587 (09 20 2021) ISSN: 2045-2322 [Electronic] England
PMID34545132 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2021. The Author(s).
Chemical References
  • Antineoplastic Agents, Immunological
  • OX40 Ligand
  • TNFSF4 protein, human
Topics
  • Antineoplastic Agents, Immunological (therapeutic use)
  • Breast Neoplasms (drug therapy, metabolism)
  • Databases, Factual
  • Humans
  • Immunotherapy (methods)
  • OX40 Ligand (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: